

Table SI. Univariate and multivariate analyses of the clinicopathological factors for the disease-free survival time in non-small cell lung carcinoma.

Clinicopathological feature	Univariate analysis			Multivariate analysis		
	HR	(95% CI)	P-value	HR	(95% CI)	P-value
Sex (male vs. female)	1.069	0.646-1.768	0.796			
Age, years (>60 vs. ≤60)	0.739	0.484-1.129	0.162			
Smoking status (smoker vs. never smoked)	0.752	0.471-1.199	0.231			
Histological type (adenocarcinoma vs. non-adenocarcinoma)	0.959	0.627-1.468	0.848	1.103	0.567-2.147	0.773
Tumor size, cm (>5 vs. ≤5)	1.077	0.986-1.177	0.098	1.471	0.880-2.457	0.141
Differentiation			0.139			0.113
Low vs. moderate	1.197	0.632-2.264	0.581	0.899	0.402-2.013	0.796
Low vs. high	0.718	0.376-1.370	0.315	0.519	0.254-1.061	0.072
Lymph node metastasis (positive vs. negative)	0.845	0.539-1.326	0.464	0.770	0.416-1.423	0.404
Stage (III vs. I, II)	1.242	0.814-1.894	0.315	1.080	0.605-1.927	0.794
CD105 expression (high vs. low)	1.285	0.840-1.965	0.247	1.119	0.696-1.800	0.642
PD-L1 expression (high vs. low)	1.628	1.066-2.485	0.024	1.072	0.625-1.839	0.801
CD68 ⁺ TAMs in tumor islets (high vs. low)	1.618	1.047-2.502	0.030	1.344	0.662-2.729	0.413
CD206 ⁺ TAMs in tumor islets (high vs. low)	1.390	0.908-2.127	0.129	1.464	0.635-3.378	0.372
CD68 ⁺ TAMs in tumor stroma (high vs. low)	1.824	1.171-2.843	0.008	1.447	0.657-3.191	0.359
CD206 ⁺ TAMs in tumor stroma (high vs. low)	1.294	0.845-1.982	0.236	0.783	0.351-1.746	0.550

CI, confidence interval; HR, hazard ratio; PD-L1, programmed cell death-ligand 1; TAMs, tumor-associated macrophages.